Ultra Nasdaq Biotechnology Proshares (BIB) 166.99

New Post Public Reply Private Reply Replies (0) Message Board

Mar 16, 2015 at 1:34 PM

Ultra Nasdaq Biotechnology Proshares (BIB) 166.99 $BIB

Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 8:30AM CDT
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF
BIIB: 419.87 (+6.52), BBC: 33.77 (+0.32), BIB: 166.99 (+6.12), XBI: 230.57 (+2.14), AMGN: 162.01 (+7.75)

12.6% Return Seen to Date on SmarTrend ProShares Ultra Nasdaq Biotechnology ETF Call (BIB)
Comtex SmarTrend(R) - Fri Mar 13, 5:13PM CDT
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on February 17th, 2015 at $142.82. In approximately 3 weeks, ProShares Ultra Nasdaq Biotechnology ETF has returned 12.64% as of today's recent price of $160.87.
BIB: 166.99 (+6.12)

3 Biotech ETFs Crushing The Market In 2015
Zacks Funds - Seeking Alpha - Fri Mar 13, 3:16PM CDT
As anyone in the biotech investing space can tell you, picking winners in this corner of the healthcare market can be extremely difficult. Failed trials, FDA concerns, and pricing issues have hit a number of companies in this sector lately, turning...
BBC: 33.77 (+0.32), BIB: 166.99 (+6.12), XBI: 230.57 (+2.14)

3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Mar 13, 11:02AM CDT
If you are looking for impressive biotech funds consider this trio, as all of its members have gained more than 20 percent so far this year.
BIIB: 419.87 (+6.52), BBC: 33.77 (+0.32), BIB: 166.99 (+6.12), XBI: 230.57 (+2.14), IBB: 351.73 (+6.40), AMGN: 162.01 (+7.75)

Biotech selling off early
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 9:04AM CST

BIB: 166.99 (+6.12), IBB: 351.73 (+6.40)

Ugly day for biotech
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 1:03PM CST

BIB: 166.99 (+6.12), IBB: 351.73 (+6.40)

Biotech off to a good start on first trading day of 2015
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:57AM CST

BIB: 166.99 (+6.12), IBB: 351.73 (+6.40)

Gilead, Abbvie, Express Scripts, And Biotech Industry Turmoil Seen By Market-Makers
Peter F. Way, CFA - Seeking Alpha - Wed Dec 24, 8:33AM CST
This is a market price forecast analysis It is not an analysis of medical technology, competition, or economics. We have limited competence in those areas. But we do have extensive experience in how market professionals have interpreted the likely...
ESRX: 83.58 (+2.21), GILD: 100.91 (+1.30), FBT: 123.19 (+2.32), BIB: 166.99 (+6.12), XBI: 230.57 (+2.14), IBB: 351.73 (+6.40), BBH: 133.25 (+2.94), ABBV: 58.91 (+0.91)

Look for Shares of ProShares Ultra Nasdaq Biotechnology ETF to Potentially Rebound after Yesterday's 9.20% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 5:13PM CST
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $116.34 to a high of $131.99. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $128.10 on volume of 948,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIB: 166.99 (+6.12)

Money flowing out of biotech today
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:40AM CST

BIS: 33.19 (-1.36), ESRX: 83.58 (+2.21), GILD: 100.91 (+1.30), BIB: 166.99 (+6.12), IBB: 351.73 (+6.40), ABBV: 58.91 (+0.91)

ProShares Ultra Nasdaq Biotechnology ETF Has Returned 22.8% Since SmarTrend Recommendation (BIB)
Comtex SmarTrend(R) - Mon Dec 15, 9:19AM CST
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on October 21st, 2014 at $104.76. In approximately 2 months, ProShares Ultra Nasdaq Biotechnology ETF has returned 22.84% as of today's recent price of $128.68.
BIB: 166.99 (+6.12)

25.1% Return Seen to Date on SmarTrend ProShares Ultra Nasdaq Biotechnology ETF Call (BIB)
Comtex SmarTrend(R) - Fri Dec 05, 4:55PM CST
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on October 21st, 2014 at $104.76. In approximately 2 month, ProShares Ultra Nasdaq Biotechnology ETF has returned 25.05% as of today's recent price of $131.00.
BIB: 166.99 (+6.12)

Shares of BIB Up 23.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 28, 11:03AM CST
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on October 21st, 2014 at $104.76. In approximately 1 month, ProShares Ultra Nasdaq Biotechnology ETF has returned 23.28% as of today's recent price of $129.14.
BIB: 166.99 (+6.12)

Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 7.71 (+0.36), BIB: 166.99 (+6.12), INCY: 90.12 (+0.81), PFE: 34.45 (+0.45), IBB: 351.73 (+6.40), DRGS: 60.08 (+1.38), BIND: 5.09 (-0.02), BMY: 67.85 (+0.98), GSK: 46.93 (+0.56), ONTY: 1.74 (-0.02), ECYT: 6.13 (-0.18), BIS: 33.19 (-1.36), CLVS: 81.11 (+3.13), AZN: 68.87 (+1.52), MRK: 57.08 (+0.88), ARIA: 8.66 (+0.18), IRY: 51.54 (+0.64), IXJ: 107.61 (+1.81), FPRX: 25.50 (-0.39)

UniQure sets price record with Glybera
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 2:33PM CST

BIS: 33.19 (-1.36), QURE: 24.99 (-0.26), BIB: 166.99 (+6.12), ALXN: 178.81 (+1.92), IBB: 351.73 (+6.40)

China mulling eliminating drug price controls
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 6:17AM CST

EWH: 21.15 (+0.18), PEK: 48.23 (+1.94), CNXT: 38.81 (+1.74), KBA: 48.89 (+1.82), BIB: 166.99 (+6.12), CQQQ: 36.60 (+0.45), IBB: 351.73 (+6.40), DRGS: 60.08 (+1.38), CHXF: 51.70 (+0.09), YINN: 36.25 (+1.85), FXP: 39.90 (-1.46), EWHS: 26.52 (+0.48), PGJ: 27.30 (-0.01), FCA: 22.86 (+0.11), YAO: 27.77 (+0.55), FCHI: 52.16 (+0.46), ASHR: 38.18 (+1.52), ASHS: 43.39 (+1.83), GXC: 80.27 (+1.12), FXI: 42.25 (+0.76), XPP: 70.65 (+2.47), KWEB: 31.56 (-0.05), ECNS: 45.38 (+0.36), TAO: 20.62 (+0.02), CHNA: 37.48 (+1.53), QQQC: 21.20 (+0.17), CHIX: 15.41 (+0.25), KFYP: 64.07 (unch), HAO: 25.19 (+0.08), MCHI: 51.78 (+0.84), CHIM: 14.67 (-0.47), YANG: 10.28 (-0.59), BIS: 33.19 (-1.36), CHIQ: 12.56 (+0.02), CHIE: 12.64 (-0.09), FHK: 40.65 (+0.32), CHII: 13.61 (+0.20), YXI: 28.04 (-0.22), CN: 36.22 (+1.17)

Drug makers face pushback on pricey meds
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 7:18AM CST

ABT: 47.70 (+0.82), BIIB: 419.87 (+6.52), BIB: 166.99 (+6.12), PFE: 34.45 (+0.45), AMGN: 162.01 (+7.75), IBB: 351.73 (+6.40), LLY: 71.11 (+1.22), DRGS: 60.08 (+1.38), GSK: 46.93 (+0.56), BMY: 67.85 (+0.98), CELG: 120.25 (+2.52), JNJ: 100.61 (+1.40), ESRX: 83.55 (+2.18), BIS: 33.19 (-1.36), MRK: 57.08 (+0.88), AZN: 68.87 (+1.52), CVS: 104.20 (+0.94), ABBV: 58.91 (+0.91), SNY: 48.71 (+1.64), IRY: 51.54 (+0.64), IXJ: 107.61 (+1.81), NVS: 97.98 (+0.94)

Histogenics on deck for IPO
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 3:30PM CST

IPO: 24.08 (+0.23), BIS: 33.19 (-1.36), BIB: 166.99 (+6.12), IBB: 351.73 (+6.40)

CB Pharma on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 10:46AM CST

IPO: 24.08 (+0.23), BIS: 33.19 (-1.36), BIB: 166.99 (+6.12), CNDO: 2.92 (-0.05), IBB: 351.73 (+6.40), DRGS: 60.08 (+1.38), IXJ: 107.61 (+1.81), IRY: 51.54 (+0.64)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Agiloft Navigates New Growth Phase with Key Leadership

Leadership Shifts Steer Agiloft's EMEA Journey Agiloft's latest shake-ups in leadership signal a determined charge through EMEA's bustling markets. Nick Bowles, a seasoned veteran in enterprise software, steps into the limelight as Senior Vice President, while Jim Leason shifts gears into a customer-focused advisory role. These aren’t just routine hiring...

HSBC Capital Move: Tender Offer Satisfaction Explained

HSBC's Capital Reshuffle: What's Gotten Sorted? If you've been eyeballing HSBC Holdings, you know they're putting some serious skin in the game. They've just wrapped up a hefty $1.5 billion tender offer for their perpetual securities, checking off a big condition known as the New Issue Condition. Diving Into the Details of the Offer Let's break this down like you're...

AppLovin Faces Serious Investor Lawsuit Deadline

Investors' Trust Shaken: The AppLovin Controversy Well, what do we have here? Another day, another hefty lawsuit coming down the pike. The spotlight’s on AppLovin Corporation (NASDAQ: APP), where the Hagens Berman law sharks are sniffing blood in the water over what they claim are federal securities law violations. The core of this legal storm swirls around AppLovin's...

Endava Faces Class Action: Investor Reactions and Next Steps

Trouble at Endava: Leadership Shakeup and Financial Concerns So, here's the kicker—Endava's got itself into one mighty mess worth chewing over with your morning coffee. When your top brass drops like flies, and you're fumbling your financials, investors start sweating bullets. On October 28, 2026, Endava plc (NYSE: DAVA) confesses to some serious accounting missteps....

WeFetch AI: A New Era in Barcode Precision

By Logan Wright Updated Nov 13, 2026 Category News Views 155

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Common ADHD Accommodations Fail to Boost Performance

Rethink ADHD Accommodations When it comes to ADHD, everyone ties the classic school accommodations to success. You give kids extra time, a quieter spot, and regular breaks, and you figure that's the magic formula, right? Well, hold onto your hats, because a fresh study out of Florida International University is flipping that script. Turns out, all those accommodations we...

HNTB Partners with Kansas City Chiefs for New Stadium

A New Chapter for the Kansas City Chiefs Are we witnessing the dawn of a new era for the Kansas City Chiefs? Officially naming HNTB as the architect for their upcoming stadium signals a strategic pivot, aimed at not just snagging eyeballs, but embedding Kansas City deeper into the sports architecture hall of fame. Unveiled during the Power Brokers Sports-Anchored...

Sino Bio Speeds AI Drug Discovery with 4RISE Launch

AI Meets Real-World Validation In the world of cutting-edge biotech, Sino Biological is turning heads with its latest move. If you're in the game of AI-driven drug discovery, their new 4RISE™ high-throughput wet-lab validation services could be the breakthrough you've been waiting for. Why? Well, the promise of AI is dazzling, but it all boils down to how fast you can...

Morgan County, IN: An Oasis for Balanced Living

Why Morgan County? A Question for Homebuyers Ever wondered what makes Morgan County, IN, such a hot ticket for folks looking to escape the daily grind of big city life? Rachel Blacklidge, real estate wizard and hometown hero, lays it all out in a way even the most city-bound among us can appreciate. Small-Town Vibes, Big-City Access Let’s face it—sometimes the chaos...

Maritime Safety Urged After New Orleans Vessel Incident

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...